Newsletter | August 24, 2026

08.24.26 -- Is It Better To Scale Up Or Scale Out Your Cell Culture Platform?

SPONSOR

The body as a bioreactor

What if therapeutic production could move from the facility into the patient? Explore how advances in lipid nanoparticle design, delivery science, and manufacturing are helping bring the body-as-a-bioreactor vision closer to reality—and reshaping what may be possible for genomic medicine.

FOCUS ON UPSTREAM MANUFACTURING

Solving Glycoengineering Challenges Could Begin At The Cell Line

Researchers produced a panel of platform cell lines illustrating how glycoform selection can be made experimentally visible earlier in biologics development.

How Can I Increase My Viral Titers And Improve The Percentage Of Full AAVs?

Explore various strategies to enhance viral titer and increase the percentage of full AAV capsids, like modifications to transfection reagents, cell lines, media, procedures, and more.

Efficient Monitoring Of Escherichia Coli Feeding Strategies

Consistent, contamination-free sampling is critical for reliable bioprocess data. Automation enables frequent, hands-free collection, improving efficiency and insight while reducing manual workload.

Is It Better To Scale Up Or Scale Out Your Cell Culture Platform?

Take a look at how adherent cell culture expansion affects space, labor, costs, contamination risk, and sustainability, helping teams weigh when a larger-footprint approach stops making sense.

Accelerating The Seed Train: Enabling N-1 Intensification

Discover how N-1 intensification shortens production timelines and improves cell viability by replacing traditional filtration with automated, low-shear separation techniques to achieve higher seeding densities.

LNP-Mediated Cell Transfection In Bioreactors Across Workflows

Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.

Disruptive Technologies Transforming Upstream Process Intensification

The demand for complex biologics is driving the need for intensified cell culture technologies. Perfusion using ATF has emerged as a leading solution to increase cell density and productivity.

A Smart Path For Novel Biologics

Learn about a solution for streamlining workflow in novel biologics while collecting quality data, by combining single-use microbioreactors with advanced automation and analytical platforms.

UPSTREAM MANUFACTURING SOLUTIONS

Building The CDMO Of The Future - FUJIFILM Biotechnologies

Accelerating CHO Bulk Harvest Testing Requires Rapid Methods - MilliporeSigma

ExPERT VLx™ Enables Gram-Scale Protein Production - MaxCyte, Inc.

In Vitro Glycoengineering: Taking Control Of Glycosylation - Roche CustomBiotech

SPONSOR

Webinar: De-Risking Cell Culture Media Scale-Up for Late-Stage Manufacturing

Scaling cell culture media manufacturing from the lab to commercial production requires balancing performance, quality, and supply reliability. Join Thermo Fisher Scientific to explore practical strategies for successful scale-up, including supply assurance, granular media benefits, evolving QC requirements, digital formulation tools, and real-world case studies. Gain insights to improve efficiency, reduce risk, accelerate commercialization, and strengthen manufacturing readiness today. Click here to learn more.

Connect With Bioprocess Online: